A recent phase Ib/2 trial testing Oleclumab in combination with Osimertinib in EGFR mutant NSCLC demonstrated safety and efficacy and is now proceeding to phase II trials (3). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.